Subscribe to Newsletter
Inside the Lab Genetics and epigenetics, Bioinformatics, Omics

Going For Gold

After careful scrutiny by a panel of judges, The Scientist magazine has announced its top 10 life science innovations of 2014 (1) and… genomics came out on top. In fact, technologies used in sequencing snagged the top five positions on the list (Table 1). The number one spot was taken by the DRAGEN Bio-IT processor from US-based company, Edico Genome.

Table 1. The top five innovations of 2014, as ranked by The Scientist.
No. Innovation Company Fast Facts
#1 DRAGEN Bio-IT Processor Edico Genome A bioinformatics processing system for fast, cost-effective analysis of genomic data
#2 MiSeqDx Illumina A next gen sequencer the size of a bread box, and the first to be FDA approved for clinical diagnostics
#3 HiSeq X Ten Illumina Illumina’s newest sequencer, which produced the $1,000 genome
#4 IrysChip V2 BioNano Genomics A sophisticated electrophoresis chamber on a chip, able to capture high res images of large genome structures
#5 Raindrop Digital PCR System RainDance Technologies A sensitive digital PCR system which can quantify rare sequences and provide gene expression information

The idea behind the processor is to shrink the effort needed for genomic analysis – instead of a group of servers, DRAGEN can store and analyze data on a small card which can be installed on a server as small as a desktop computer. According to CEO Pieter van Rooyen, it can also drastically reduce analysis time. “The card is available on a pre-configured server that can be easily integrated into a next generation sequencing (NGS) bioinformatics pipeline,” he says. “The processor is loaded with optimized algorithms for NGS analysis including decompression, mapping, aligning, sorting, and haplotype variant calling.

0215-207-main-450

This can reduce the time it takes to analyze a whole human genome at 30X coverage from 24 hours to just 24 minutes. It could also reduce the costs of storage and IT infrastructure,” he explains.

So what are Edico’s plans for DRAGEN? “Sequenom is our first customer, and our technology is also being used by the University of California, San Diego, US. We only began selling DRAGEN a few months ago, but we are talking with a number of potential partners and customers – ranging from small startups to well established companies, to academic institutions and even government agencies. Potential future areas include clinical genomics, especially cancer genomics, and non-invasive prenatal testing, which I think will grow tremendously in coming years.”

Looking ahead, Edico want to extend the platform beyond the genome, exome and panel workflows they currently offer, to include RNA-seq, cancer, transcriptome, methylome and microbiome analysis. “We are honored and humbled to have been named the number one innovation of 2014 – it’s a true testament to the hard work and dedication of our team,” says van Rooyen.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. The Scientist, “Top 10 Innovations 2014”, (2014). Available at: bit.ly/12jXGIZ. Accessed February 11, 2015.
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Application Notes
Evaluation of cell-free fetal DNA to determine fetal RhD status

| Contributed by Revvity

Preventing Bias in scRNAseq Performed on Solid Tumors

| Contributed by Revvity

Enabling Efficient, Cost-effective Sequencing of the Human Whole Exome

| Contributed by Revvity

Related Product Profile
Diagnostics Genetics and epigenetics
QIAseq® Pan Cancer Multimodal cuts user interventions by 50%

| Contributed by QIAGEN

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register